Ibrutinib treatment leads to H3K27ac redistribution in chronic lymphocytic leukemia
Lambe A, Barth N, Papakonstantinou N, Xanthopoulos C, Gounari M, Stamatopoulos K, Taher L, Kostareli E (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: TAYLOR & FRANCIS LTD
City/Town: ABINGDON
Pages Range: 252-253
Conference Proceedings Title: LEUKEMIA & LYMPHOMA
Authors with CRIS profile
Involved external institutions
Centre for Research and Technology Hellas (CERTH) / Ethniko Kentro Erevnas Kai Technologikis Anaptyxis
Greece (GR)
Eidgenössische Technische Hochschule Zürich (ETHZ) / Swiss Federal Institute of Technology in Zurich
Switzerland (CH)
Queen's University
United Kingdom (GB)
Greece (GR)
Eidgenössische Technische Hochschule Zürich (ETHZ) / Swiss Federal Institute of Technology in Zurich
Switzerland (CH)
Queen's University
United Kingdom (GB)
How to cite
APA:
Lambe, A., Barth, N., Papakonstantinou, N., Xanthopoulos, C., Gounari, M., Stamatopoulos, K.,... Kostareli, E. (2020). Ibrutinib treatment leads to H3K27ac redistribution in chronic lymphocytic leukemia. In LEUKEMIA & LYMPHOMA (pp. 252-253). ABINGDON: TAYLOR & FRANCIS LTD.
MLA:
Lambe, Adam, et al. "Ibrutinib treatment leads to H3K27ac redistribution in chronic lymphocytic leukemia." Proceedings of the LEUKEMIA & LYMPHOMA ABINGDON: TAYLOR & FRANCIS LTD, 2020. 252-253.
BibTeX: Download